Same molecule, different products. The distinction matters more than you'd think—especially for insurance and dosing.
The short answer: yes and no. Wegovy and Ozempic both contain semaglutide—the same GLP-1 receptor agonist molecule manufactured by Novo Nordisk. But calling them "the same drug" misses important differences in dose, indication, titration schedule, and how insurance treats them.
Understanding the distinction can save you thousands of dollars and prevent insurance headaches. Here's the complete picture.
Semaglutide is a GLP-1 (glucagon-like peptide-1) receptor agonist. It mimics a naturally occurring gut hormone that:
These mechanisms are why semaglutide is effective both for Type 2 diabetes management and for weight loss—the drug does both things. The question is which indication is the intended therapeutic target, and that's where Ozempic and Wegovy diverge.
| Ozempic | Wegovy | |
|---|---|---|
| Active ingredient | Semaglutide | Semaglutide |
| FDA indication | Type 2 diabetes; CV risk reduction in T2D with established CVD | Chronic weight management (BMI ≥30, or ≥27 with comorbidity) |
| Available doses | 0.5mg, 1mg, 2mg/week | 0.25mg, 0.5mg, 1mg, 1.7mg, 2.4mg/week |
| Maximum maintenance dose | 2mg/week | 2.4mg/week |
| FDA approval year | 2017 | 2021 |
| List price (approx.) | ~$935/month | ~$1,349/month |
| Insurance coverage | Most plans cover for T2D; rarely for weight loss | Covered by plans that include weight loss drugs; excluded by many |
The most clinically significant difference between Wegovy and Ozempic is the maximum dose. Wegovy goes up to 2.4mg/week; Ozempic maxes at 2mg/week. This 20% higher dose produces meaningfully greater weight loss in clinical trials.
The STEP-1 trial (Wegovy at 2.4mg) showed 14.9% average weight loss over 68 weeks. Ozempic trials in T2D populations at 1–2mg doses showed 5–9% weight loss—but this lower number reflects both the lower dose and the T2D population, where metabolic dynamics differ.
In a non-diabetic population at equivalent doses, the efficacy of Ozempic and Wegovy is similar. The additional benefit of Wegovy comes primarily from that 0.4mg higher ceiling dose.
The titration schedules differ slightly between the two products:
Ozempic titration:
Wegovy titration:
Wegovy's slower titration with an intermediate 1.7mg dose before reaching 2.4mg is designed to improve GI tolerability at the higher dose. The extra step matters—jumping straight to 2.4mg would cause more side effects.
The FDA approves drugs for specific indications. When a drug is used for an indication not listed in its approval, that's called "off-label" use. Off-label prescribing is legal and common in medicine, but it has practical consequences:
Most insurance plans will only cover a drug for its approved indication. Ozempic is approved for T2D—your insurance will cover it if you have T2D and meet their criteria. If your doctor prescribes Ozempic for weight loss (an off-label use), insurance will deny coverage with the reason "not medically necessary" or "indication not covered."
Wegovy is approved for weight management—your insurance will cover it if your plan includes weight loss drugs and you meet BMI/comorbidity criteria. Not all plans include weight loss drugs.
A prescriber can legally write Ozempic for weight loss off-label. But if you then submit that to insurance as a weight loss treatment, it will be denied. Some providers use T2D diagnosis codes even for patients who are only borderline or prediabetic—this is billing fraud, even if done with good intentions, and creates liability for your provider.
Clinically: yes. Ozempic suppresses appetite and promotes weight loss through the same mechanism as Wegovy. If you have Type 2 diabetes and your doctor prescribes Ozempic, you will likely experience meaningful weight loss alongside blood sugar improvement.
If you don't have Type 2 diabetes and want to use Ozempic for weight loss:
Wegovy's list price (~$1,349/month) is higher than Ozempic (~$935/month) despite containing the same active ingredient. This is entirely a market pricing decision by Novo Nordisk. The obesity market is separate from the diabetes market in formulary design, and Novo Nordisk priced Wegovy independently.
In practice, what you pay out of pocket may be similar:
One genuinely distinct advantage of Ozempic over Wegovy is its cardiovascular outcomes data. The SUSTAIN-6 and SELECT trials demonstrated that semaglutide reduces major adverse cardiovascular events (heart attack, stroke, cardiovascular death) in patients with Type 2 diabetes and established cardiovascular disease.
The SELECT trial, published in 2023, extended this to non-diabetic patients with obesity and established CVD—showing a 20% reduction in MACE. This cardiovascular benefit is significant for patients at elevated cardiac risk, not just for blood sugar or weight management.
Wegovy has the same active molecule and thus presumably the same cardiovascular benefit, but the labeled indication doesn't yet include cardiovascular risk reduction for weight management patients (this may change as regulatory submissions are made).
You have Type 2 diabetes: Ozempic is the appropriate FDA-approved choice. It will also help with weight. Coverage is more broadly available. If cardiovascular protection is a goal, the evidence base is strong.
You need weight loss without T2D: Wegovy is the approved option. The 2.4mg dose produces the best weight loss outcomes in clinical trials. Check whether your plan covers weight loss drugs.
You're comparing efficacy: Use our GLP-1 Drug Comparison to see Wegovy vs. Ozempic vs. Mounjaro vs. Zepbound side by side with weight loss outcome data.
Yes, a doctor can switch you between Ozempic and Wegovy. They contain the same active ingredient, so there's no pharmacological incompatibility. The switch is typically made when a patient on Ozempic for T2D also wants to maximize weight loss benefits—Wegovy goes to a higher dose (2.4mg). Insurance coverage may change with the switch depending on your indication and plan.
Wegovy reaches a higher maximum dose (2.4mg/week vs. 2mg/week), which produces slightly greater weight loss at the maximum dose. At equivalent doses (e.g., both at 1mg or both at 2mg), they are pharmacologically identical. The clinical trial weight loss results for Wegovy appear better largely because the trials used the higher 2.4mg dose in a non-diabetic population.
Wegovy contains the same semaglutide molecule and would produce similar blood sugar benefits—but it's not labeled or studied for diabetes management specifically. If you have T2D, Ozempic is the appropriate, indicated choice. Using Wegovy for diabetes would be off-label, and your insurance is more likely to cover Ozempic for that indication.
See Ozempic, Wegovy, Mounjaro, and Zepbound compared side by side on efficacy, cost, and side effects.
Compare GLP-1 Drugs →Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Drug pricing, insurance coverage, and FDA labeling information may change. Always consult a licensed healthcare provider before starting, switching, or stopping any medication.
Compare Providers
These providers offer online consultations, licensed prescribers, and medication shipped to your door.
GLP-1 specialist. Fast evaluation, compounded semaglutide & tirzepatide, competitive pricing.
Get Started →High patient satisfaction. Compounded semaglutide at lower cost. No in-person visit required.
Get Started →Connects patients with licensed GLP-1 prescribers. Multiple medication options, ongoing support.
Get Started →Compare all GLP-1 providers → • Sponsored links. Medical evaluation required. Results vary. See full provider comparison.